AceLink consists of a seasoned team of drug development professionals, consultants, and advisors with a rich knowledge of glycolipid biology, kidney disease, and drug development. We collaborate with an experienced network of contract research organizations, academics, and key opinion leaders (KOLs). This model allows us to efficiently transform scientific discoveries into impactful new therapies.
AceLink’s lead programs
AL01211 is a non-brain penetrant GCS (glucosylceramide synthase) inhibitor with superior properties to other GCS inhibitors currently in development. AL01211 is in Phase 1 clinical trials and will enter Phase 2 trials in 2022 for Fabry disease. AL01211 also has potential benefits for several kidney diseases such as polycystic kidney disease, kidney fibrosis, and diabetic nephropathy.
AL00804 is a highly brain penetrant GCS inhibitor being developed for the treatment of neuropathic glycolipid storage diseases including Gaucher disease, GM2 gangliosidosis (Tay-Sach and Sandhoff disease), GM1 gangliosidosis, and possibly certain genetic forms of Parkinson’s disease.